Search Results
Apr 28, 2026, 15:40 ET Piramal Pharma Limited Announces Results for Q4 and Full-year FY26
(3) % CDMO1,708
More news about: Piramal Pharma Limited
Apr 28, 2026, 13:39 ET Small Molecule API Market to Reach USD 202.53 Billion by 2036, Driven by Generic Drug Demand and Expanding Oncology Pipeline
https://www.futuremarketinsights.com/reports/small-molecule-brominated-flame-retardants-marketSmall Molecule CDMO Market: https://www.futuremarketinsights.com/reports/small-molecule-cdmo-marketSmall Molecule-Drug Conjugates Market:
More news about: Future Market Insights
Apr 28, 2026, 11:00 ET Mikart Celebrates Ribbon Cutting of New Atlanta Headquarters, Marking Major Milestone in Growth and Expansion
ATLANTA, April 28, 2026 /PRNewswire/ -- Mikart, a leading contract development and manufacturing organization (CDMO), today celebrated the official ribbon cutting of its new headquarters in Northwest Atlanta. The new executive headquarters represents a significant
More news about: Mikart, LLC
Apr 28, 2026, 08:01 ET PharmaLogic announces opening of new PET radiopharmaceutical manufacturing facility in Atlanta, Georgia
PharmaLogic Holdings Corp., ("PharmaLogic" or "the Company"), a leading contract development and manufacturing organization (CDMO) specializing in radiopharmaceuticals, today announces the opening of its new PET radiopharmaceutical manufacturing facility in Atlanta, Georgia. The
More news about: PharmaLogic Holdings Corp
Apr 28, 2026, 08:01 ET VALION BIO BRIEFS PENTAGON LEADERSHIP ON ENTOLIMOD™ FOR ACUTE RADIATION SYNDROME
oncology supportive care. Valion Bio's wholly owned subsidiary, Velocity Bioworks, is a full-service contract development and manufacturing organization (CDMO) that provides biomanufacturing services to third-party biotech companies. Valion Bio also leverages Velocity Bioworks' manufacturing capabilities to
More news about: Valion Bio, Inc.
Apr 28, 2026, 08:00 ET Genezen and The Charlotte & Gwenyth Gray Foundation to Cure Batten Disease Announce Manufacturing Partnership for CLN6 Gene Therapy Clinical Trial
ANGELES, April 28, 2026 /PRNewswire/ -- Genezen, a gene therapy contract development and manufacturing organization (CDMO), and The Charlotte & Gwenyth Gray Foundation to Cure Batten Disease today announced a manufacturing partnership to advance a CLN6 gene therapy into
More news about: Genezen
Apr 27, 2026, 05:03 ET WuXi AppTec Delivers Strong Revenue and Profit Growth in Q1 2026
of our CRDMO business.Small molecule D&M service maintains strong momentum.i. The small molecule CDMO pipeline continued to expand, adding 328 new molecules in the first quarter of 2026. As of March 31, 2026, our pipeline reached 3,550 molecules, including
More news about: WuXi AppTec
Apr 24, 2026, 08:30 ET Quasar Medical Celebrates Grand Opening of New Manufacturing Facility in Thailand
involvement.In addition to Quasar's existing network across Asia, North America, and Europe, the new site enhances the company's vertically integrated CDMO model, covering everything from design and development to commercialization. This continuous investment underscores Quasar's dedication to providing
More news about: Quasar Medical
Apr 24, 2026, 08:00 ET Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing
by institutional life sciences investor, with participation from new and existing investorsCapital expected to support expansion of CDMO platform and advancement of customer programsJERUSALEM, April 24,
More news about: Scinai Immunotherapeutics Ltd.
Apr 23, 2026, 16:05 ET Tivic Health Systems Rebrands as Valion Bio, Reflecting Completed Transformation into a Late-Stage Biopharmaceutical Company with Government-Backed Asset and Potential Multiple Revenue Stream Model
VBIO Effective April 28, 2026; Company Advancing Entolimod™ Toward BARDA Funding and Strategic National Stockpile Procurement While Velocity Bioworks CDMO Builds Independent Revenue BaseSAN ANTONIO, April 23, 2026 /PRNewswire/
More news about: Tivic Health Systems, Inc.
Apr 23, 2026, 07:30 ET Mikart and Benuvia Announce Strategic Co-Marketing Partnership to Deliver End-to-End Controlled Substance Development and Finished Drug Product Manufacturing Solutions
and manufacturing organization (CDMO) specializing in formulation development, analytical testing, and manufacturing of oral solid and liquid dose drug products, including controlled substances. About Benuvia Benuvia Operations, LLC is a US-based CDMO specializing in drug development and
More news about: Mikart, LLC
Apr 22, 2026, 09:30 ET Made Scientific and Regenicin Announce Manufacturing Relationship to Advance NovaDerm Toward FDA Product Approval
manufacturing organization (CDMO) specializing in the development, manufacturing, and release of autologous and allogeneic cell therapy products for clinical and commercial supply. Headquartered in Princeton, New Jersey, Made Scientific combines the agility of a specialist CDMO with the deep technical expertise
More news about: Made Scientific, Inc.
Apr 22, 2026, 02:50 ET Samsung Biologics Reports First Quarter 2026 Financial Results
April 22, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), reported financial results for the first quarter of fiscal year 2026.
More news about: Samsung Biologics
Apr 21, 2026, 12:15 ET TOSLA and Geltor Launch the First Vegan Signaling Collagen Liquid Supplement, Powered by PrimaColl®, a Type 21 Signaling Collagen
forward to, because when wellness becomes a ritual, adherence follows, and results are realized over time."As a global leader in next-generation CDMO solutions, TOSLA specializes in translating advanced scientific innovation into scalable, compliant, and consumer-ready liquid formats through scientific
More news about: TOSLA
Apr 21, 2026, 11:11 ET Alcami to Acquire Contract Packaging Organization Tjoapack
Strategic integration creates an end-to-end global CDMO platform with U.S.-Europe supply chain redundancy for pharmaceutical and biotech companiesWILMINGTON, N.C., April 21, 2026 /PRNewswire/ --
More news about: Alcami
Apr 21, 2026, 08:00 ET Andelyn Biosciences and ENCell Co., Ltd Announce Strategic Partnership to Expand Global Reach of Gene Therapy Manufacturing
("Andelyn") a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization ("CDMO"), and ENCell Co., Ltd. ("ENCell"), a Korea-based advanced biopharmaceutical CDMO, announced today the signing of a Collaboration Agreement to establish a strategic manufacturing bridge between
More news about: Andelyn Biosciences
Apr 21, 2026, 08:00 ET Minaris Delivers 100% Manufacturing and Release Success for Chimeric Therapeutics' CDH17 Autologous CAR‑T Program
April 21, 2026 /PRNewswire/ -- Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality biosafety testing provider and Chimeric Therapeutics (ASX: CHM, "Chimeric" or the "Company"), a leading Australian cell therapy company,
More news about: Minaris Advanced Therapies
Apr 21, 2026, 08:00 ET Minaris Delivers 100% Manufacturing and Release Success for Chimeric Therapeutics' CDH17 Autologous CAR‑T Program
April 21, 2026 /PRNewswire/ -- Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality biosafety testing provider and Chimeric Therapeutics (ASX: CHM, "Chimeric" or the "Company"), a leading Australian cell therapy company,
More news about: Minaris Advanced Therapies
Apr 17, 2026, 04:19 ET Piramal Pharma Solutions e Ajinomoto Bio-Pharma Services collaborano per supportare lo sviluppo e la produzione di ADC
17 aprile 2026 /PRNewswire/ -- Piramal Pharma Solutions, una Contract Development and Manufacturing Organization (CDMO) leader a livello globale e parte di Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), e Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"),
More news about: Piramal Pharma Solutions
Apr 16, 2026, 16:14 ET Piramal Pharma Solutions et Ajinomoto Bio-Pharma Services collaborent pour soutenir le développement et la fabrication de CAM
16 avril 2026 /PRNewswire/ -- Piramal Pharma Solutions, une organisation mondiale de développement et de fabrication sous contrat (CDMO) de premier plan, qui fait partie de Piramal Pharma Ltd. (NSE : PPLPHARMA) (BSE : 543635), et Ajinomoto Bio-Pharma Services (« Aji Bio-Pharma »),
More news about: Piramal Pharma Solutions
Apr 16, 2026, 13:12 ET Piramal Pharma Solutions und Ajinomoto Bio-Pharma Services arbeiten zusammen, um die Entwicklung und Herstellung von ADCs zu unterstützen
16. April 2026 /PRNewswire/ -- Piramal Pharma Solutions, ein weltweit führendes Unternehmen für Auftragsentwicklung und -herstellung (CDMO) und Teil von Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), und Ajinomoto Bio-Pharma Services („Aji Bio-Pharma"), ein führender Anbieter
More news about: Piramal Pharma Solutions
Apr 16, 2026, 08:30 ET Piramal Pharma Solutions y Ajinomoto Bio-Pharma Services colaboran en el desarrollo y fabricación de ADC
16 de abril de 2026 /PRNewswire/ -- Piramal Pharma Solutions, una organización líder mundial en desarrollo y fabricación por contrato (CDMO, por sus siglas en inglés) y parte de Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), y Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), un proveedor
More news about: Piramal Pharma Solutions
Apr 16, 2026, 08:00 ET Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services Collaborate to Support ADC Development and Manufacturing
April 16, 2026 /PRNewswire/ -- Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), and Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of
More news about: Piramal Pharma Solutions
Apr 16, 2026, 08:00 ET Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services Collaborate to Support ADC Development and Manufacturing
April 16, 2026 /PRNewswire/ -- Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), and Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of
More news about: Piramal Pharma Solutions
Apr 16, 2026, 08:00 ET Crystal Pharmatech Becomes First Company in Asia-Pacific to Deploy Dedicated MicroED Platform Through Strategic Collaboration with ELDICO Scientific
SUZHOU, China, April 16, 2026 /PRNewswire/ -- Crystal Pharmatech is a science-driven CRO/CDMO specializing in solid-state research, preformulation studies, and formulation development and manufacturing for small molecule drugs. The company operates
More news about: Crystal Pharmatech